세계의 안구건조증 치료 시장 : 약제별, 제형별, 유통 채널별 기회 분석 및 산업 예측(2023-2032년)

Dry Eye Syndrome Treatment Market By Drug, By Dosage form, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,891,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,221,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계의 안구건조증 치료(Dry Eye Syndrome Treatment) 시장 규모는 2022년에 47억 2,500만 달러였으며, 2023-2032년에 CAGR 7.1%로 추이하며 성장할 것으로 예상되며, 2032년에는 93억 1,650만 달러에 달할 것으로 예측됩니다.

안구건조증은 환자의 눈물이 눈에 충분한 윤활유를 공급하지 못할 때 발생하는 흔한 질환입니다. 안구건조증(DED)은 안구건조증(DES), 유행성 각결막염(KCS), 유행성 각결막염으로도 알려져 있으며, 눈물막의 항상성 상실로 인한 안구 표면의 다인성 질환입니다.

안구건조증 치료 시장의 성장은 노인 인구의 증가, 안구건조증 유병률 급증, 효과적인 치료법에 대한 수요 증가에 의해 주도되고 있습니다. 노인의 경우 눈물을 생성하는 눈물샘의 효율성이 감소합니다. 따라서 눈물 생성 부족은 노인의 안구건조증으로 이어집니다. 예를 들어, 유나이티드 헬스 재단이 발표한 미국 건강 순위 보고서에 따르면 2021년 미국에는 65세 이상 성인이 5,400만 명 이상 거주하고 있으며 이는 미국 인구의 약 16.5%에 달하는 것으로 추정됩니다.

또한 대형 의료 기술 기업들이 안구건조증 치료 솔루션을 제공하는 기업을 인수하는 데 점점 더 집중하고 있으며, 이는 시장 성장에 크게 기여할 것으로 예상됩니다. 글로벌 안구건조증 치료제 시장의 주요 업체들은 시장에서의 입지를 강화하고 경쟁 환경을 유지하기 위해 안구건조증 치료제 발전을 위한 제품 출시, 인수, R&D 투자 등 다양한 전략을 채택하고 있습니다. 예를 들어, 2023년 1월, 세계 헬스케어 기업인 Viatris Inc.는 Oyster Point Pharma와 Famy Life Sciences의 완전 인수를 발표하고 Viatris Eye Care 부문을 새로 설립했습니다.

또한 안구건조증(DED) 유병률의 급격한 증가, 안구건조증 치료 기술의 발전, 콘택트렌즈의 장기 사용은 시장 성장을 이끄는 주요 요인 중 일부입니다. 또한 광범위한 화면 사용 시간과 컴퓨터 기반 작업은 안구건조증(DES) 유병률 증가에 크게 기여하고 있습니다. 그러나 약물 승인에 대한 엄격한 규제 절차와 숙련된 안과 의사의 부족은 시장 성장을 제한할 수 있습니다. 반대로, 노인 인구의 안구건조증 치료 적용 증가와 최근 출시 된 약물은 가까운 장래에 시장 성장을위한 수익성있는 기회를 제공 할 것으로 예상됩니다. 또한 의료 인프라의 상당한 개선과 함께 안구 건조증 치료 분야의 광범위한 연구 개발 활동은 예측 기간 동안 시장 확장을위한 새로운 길을 열 것으로 예상됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향 요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진 요인
    • 안구건조증 증가
    • 스크린 사용 시간 증가와 콘택트렌즈 채택 증가
    • 고령자 인구 증가
  • 억제 요인
    • 안구건조증에 대한 인식 부족
  • 기회
    • 최신 제품 승인과 높은 미개척 시장 잠재력

제4장 안구건조증 치료 시장 : 약제별

• 개요
• 윤활제
• 안구건조증 치료
• 기타

제5장 안구건조증 치료 시장 : 제형별

• 개요
• 점안약
• 연고
• 기타

제6장 안구건조증 치료 시장 : 유통 채널별

• 개요
• 원내 약국
• 소매 약국
• 온라인 제공업체

제7장 안구건조증 치료 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아 태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타
• 남미, 중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 구도

• 소개
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제9장 기업 개요

• AbbVie Inc.
• Viatris Inc.
• Novartis AG
• Bausch Health Companies Inc
• Sun Pharmaceutical Industries Ltd.
• Novaliq
• Santen Pharmaceutical Co., Ltd.
• AFT Pharmaceuticals Limited
• Alcon
• Johnson & Johnson(J&J)

LYJ

영문 목차

영문목차

The Dry Eye Syndrome Treatment Market was valued for $4,725.00 million in 2022 and is estimated to reach $9,316.50 million by 2032, exhibiting a CAGR of 7.1% from 2023 to 2032.

Dry eye disease is a common condition that occurs when a patient's tears are unable to provide adequate lubrication for their eyes. Dry eye disease (DED), also known as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film.

The growth of the dry eye syndrome treatment market is driven by rise in geriatric population, surge in prevalence of dry eye diseases, and increase in demand for effective treatment. In the geriatric people, there is decrease in efficiency of lacrimal glands to produce tears. Thus, lack of tears production leads to dry eye condition in geriatric people. For instance, according to the report published by the America's Health Ranking by United Health Foundation, in 2021, it has been estimated that more than 54 million adults aged 65 and older live in the U.S., which is about 16.5% of the nation's population.

Moreover, large medical technology firms have increasingly focused on acquiring companies that provide solutions for dry eye syndrome treatments, which is expected to notably contribute toward the market growth. Prominent players in the global dry eye syndrome treatment market have adopted various strategies such as product launches, acquisitions, and investments in R&D for advancement in dry eye syndrome treatments to strengthen their position in the market and sustain the competitive environment. For instance, in January 2023, Viatris Inc., a global healthcare company, announced its complete acquisition of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division.

Moreover, alarming increase in prevalence of dry eye diseases (DED), technological advancements in dry eye syndrome treatment, and long-term use of contact lens are some of the key factors that drive the growth of the market. Furthermore, extensive screen time and computer-based work notably contribute toward the growth in prevalence of dry eye syndrome (DES). However, stringent regulatory process for drug approval and dearth of skilled ophthalmologists may restrain the market growth. Conversely, increased application of dry eye syndrome treatment among the geriatric population and recent drug launched in market is expected to provide lucrative opportunities for the growth of the market in the near future. In addition, extensive R&D activities in the field of dry eye syndrome treatment along with significant improvement in medical infrastructure are anticipated to open new avenues for the expansion of the market during the forecast period.

The dry eye syndrome treatment market is segmented into drug, dosage form, distribution channel, and region. On the basis of drug, the market is classified into lubricant, dry eye syndrome drugs and others. On the basis of dosage form, the market is categorized into eye drops, ointments, and others. On the basis of distribution channel, it is classified into hospital pharmacies, retail pharmacies and online providers. On the basis of region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major companies profiled in the report include Abbvie, Viatris, Novartis AG, Bausch & Lomb Incorporated, Sun Pharma, Novaliq, Santen Pharmaceutical Co., AFT Pharmaceuticals, Alcon and Johnson & Johnson.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dry eye syndrome treatment market analysis from 2022 to 2032 to identify the prevailing dry eye syndrome treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the dry eye syndrome treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global dry eye syndrome treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• New Product Development/ Product Matrix of Key Players
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• SWOT Analysis

Key Market Segments

By Drug

• Lubricant
• Dry eye syndrome drugs
• Others

By Dosage form

• Eye drops
• Ointments
• Other

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• AbbVie Inc.
• Viatris Inc.
• Novartis AG
• Bausch Health Companies Inc
• Novaliq
• AFT Pharmaceuticals Limited
• Alcon
• Johnson & Johnson (J&J)
• Santen Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in prevalence of dry eye syndrome
    • 3.4.1.2. Increase in screen time and rise in adoption of contact lens
    • 3.4.1.3. Upsurge in geriatric population
  • 3.4.2. Restraints
    • 3.4.2.1. Lack of awareness about dry eye syndrome
  • 3.4.3. Opportunities
    • 3.4.3.1. Latest product approvals and high untapped market potential

CHAPTER 4: DRY EYE SYNDROME TREATMENT MARKET, BY DRUG

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Lubricant
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Dry eye syndrome drugs
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: DRY EYE SYNDROME TREATMENT MARKET, BY DOSAGE FORM

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Eye drops
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Ointments
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Other
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Retail pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online providers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: DRY EYE SYNDROME TREATMENT MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Drug
  • 7.2.3. Market size and forecast, by Dosage form
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Drug
    • 7.2.5.1.2. Market size and forecast, by Dosage form
    • 7.2.5.1.3. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Drug
    • 7.2.5.2.2. Market size and forecast, by Dosage form
    • 7.2.5.2.3. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Drug
    • 7.2.5.3.2. Market size and forecast, by Dosage form
    • 7.2.5.3.3. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Drug
  • 7.3.3. Market size and forecast, by Dosage form
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Drug
    • 7.3.5.1.2. Market size and forecast, by Dosage form
    • 7.3.5.1.3. Market size and forecast, by Distribution Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Drug
    • 7.3.5.2.2. Market size and forecast, by Dosage form
    • 7.3.5.2.3. Market size and forecast, by Distribution Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Drug
    • 7.3.5.3.2. Market size and forecast, by Dosage form
    • 7.3.5.3.3. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Drug
    • 7.3.5.4.2. Market size and forecast, by Dosage form
    • 7.3.5.4.3. Market size and forecast, by Distribution Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Drug
    • 7.3.5.5.2. Market size and forecast, by Dosage form
    • 7.3.5.5.3. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Drug
    • 7.3.5.6.2. Market size and forecast, by Dosage form
    • 7.3.5.6.3. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Drug
  • 7.4.3. Market size and forecast, by Dosage form
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. China
    • 7.4.5.1.1. Market size and forecast, by Drug
    • 7.4.5.1.2. Market size and forecast, by Dosage form
    • 7.4.5.1.3. Market size and forecast, by Distribution Channel
    • 7.4.5.2. Japan
    • 7.4.5.2.1. Market size and forecast, by Drug
    • 7.4.5.2.2. Market size and forecast, by Dosage form
    • 7.4.5.2.3. Market size and forecast, by Distribution Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Drug
    • 7.4.5.3.2. Market size and forecast, by Dosage form
    • 7.4.5.3.3. Market size and forecast, by Distribution Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Drug
    • 7.4.5.4.2. Market size and forecast, by Dosage form
    • 7.4.5.4.3. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Drug
    • 7.4.5.5.2. Market size and forecast, by Dosage form
    • 7.4.5.5.3. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Drug
    • 7.4.5.6.2. Market size and forecast, by Dosage form
    • 7.4.5.6.3. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Drug
  • 7.5.3. Market size and forecast, by Dosage form
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Drug
    • 7.5.5.1.2. Market size and forecast, by Dosage form
    • 7.5.5.1.3. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Drug
    • 7.5.5.2.2. Market size and forecast, by Dosage form
    • 7.5.5.2.3. Market size and forecast, by Distribution Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Drug
    • 7.5.5.3.2. Market size and forecast, by Dosage form
    • 7.5.5.3.3. Market size and forecast, by Distribution Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Drug
    • 7.5.5.4.2. Market size and forecast, by Dosage form
    • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. AbbVie Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Viatris Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Novartis AG
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
• 9.4. Bausch Health Companies Inc
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Sun Pharmaceutical Industries Ltd.
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Novaliq
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Key strategic moves and developments
• 9.7. Santen Pharmaceutical Co., Ltd.
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. AFT Pharmaceuticals Limited
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Alcon
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Johnson & Johnson (J&J)
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance

관련자료